任何在潜伏结核分枝杆菌感染治疗期间出现的导致住院或者死亡的不良反应需及时上报当地或国家卫生部门以便纳入国家监管的LTBI治疗严重不良反应资料数据(邮箱:ltbidrugevents@ cdc.gov)。
严重的药物副作用、药物质量问题以及治疗失败案例需向食品和药物监督管理局上报:(https://www.fda.gov/Safety/MedWatch/HowToReport/default.htm) 或致电1-800-FDA-1088。
其他的关于3HP治疗的资料可在:
https://www.cdc.gov/tb/publications/ltbi/ltbiresources.htm.网站上获得。如有问题可直接向CDC消除肺结核部门联系,邮箱(cdcinfo@cdc.gov)或致电800-CDC-INFO(800-232-4636)。
利益冲突:无
参考文献:
1. CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011;60:1650–3.
2. Briss PA, Zaza S, Pappaioanou M, et al.; The Task Force on Community Preventive Services. Developing an evidence-based Guide to Community Preventive Services—methods. Am J Prev Med 2000;18(Suppl):35–43.
https://doi.org/10.1016/S0749-3797(99)00119-1
3. Zaza S, Wright-De Agüero LK, Briss PA, et al.; Task Force on Community Preventive Services. Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. Am J Prev Med
2000;18(Suppl):44–74. https://doi.org/10.1016/S0749-3797(99)00122-1
4. Njie GJ, Morris SB, Woodruff RY, Moro RN, Vernon AA, Borisov AS. Isoniazid-rifapentine for latent tuberculosis infection: a systematic review and meta-analysis. Am J Prev Med 2018. Epub June 11, 2018. https://
doi.org/10.1016/j.amepre.2018.04.030
5. Villarino ME, Scott NA, Weis SE, et al.; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr 2015;169:247–55. https://doi.org/10.1001/jamapediatrics.2014.3158
6. Sterling TR, Scott NA, Miro JM, et al.; Tuberculosis Trials Consortium; AIDS Clinical Trials Group for the PREVENT TB Trial. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS 2016;30:1607–15. https://doi.org/10.1097/QAD.0000000000001098
7. Weiner M, Egelund EF, Engle M, et al. Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers. J Antimicrob Chemother 2014;69:1079–85. https://doi.org/10.1093/jac/dkt483
8. Podany AT, Bao Y, Swindells S, et al.; AIDS Clinical Trials Group A5279 Study Team. Efavirenz pharmacokinetics and pharmacodynamics in HIVinfected persons receiving rifapentine and isoniazid for tuberculosis prevention. Clin Infect Dis 2015;61:1322–7. https://doi.org/10.1093/cid/civ464
9. Belknap R, Holland D, Feng PJ, et al.; TB Trials Consortium iAdhere Study Team. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med 2017;167:689–97.
10. Sterling TR, Moro RN, Borisov AS, et al.; Tuberculosis Trials Consortium. Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT Tuberculosis study. Clin Infect Dis 2015;61:527–35. https://doi.org/10.1093/cid/civ323